Sestrin-2 Levels and Insulin Resistance | Clinical Trial

Key information

Conditions

Obese Adolescents Body Weight Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pediatric Obesity Signs and Symptoms

Age range

10 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kayseri City Hospital

Kayseri, 38125, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2

Exclusion criteria

Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes

Treatment and study plan

Sestrin-2

Other

Sestrin-2 levels were studied in three different groups

Primary outcomes

Evaluation of sestrin-2 levels in obese and healthy participants

Time frame: From enrollment to the end of 6 months

Sponsors and collaborators

Lead sponsor

Kayseri City Hospital

Other Gov

Registry information

Official study title

Sestrin-2 Levels and Insulin Resistance in Childhood Obesity

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Jan 16, 2025
Registry last updated: Jan 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting